Editas Medicine, Inc. (EDIT) stock
EDITNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 3/3047% above fair value
$2.38−0.13 (-4.99%)
Close on Nov 11, 2026Market cap $365.52MP/E –Yield –
Earnings
Editas Medicine's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
Mar 8, 2027
Q4 FY2026 · estimated, before the open
Revenue, Q3 FY2026
$10.40M
+38.7% on a year earlier
EPS, Q3 FY2026
-$0.15
-$0.28 a year earlier
Latest guidance
None
No outlook given in releases
Quarterly results
Revenue and earnings per share from each of Editas Medicine's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Mar 8, 2027Expected | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Nov 9, 2026before the open | $10.40M | +38.7% | -$0.15 | Release |
| Q2 FY2026ended Jun 30, 2026 | Aug 5, 2026after the close | $11.90M | +230.6% | -$0.15 | Release |
| Q1 FY2026ended Mar 31, 2026 | May 5, 2026before the open | – | – | – | Release |
| Q4 FY2025ended Dec 31, 2025 | Mar 9, 2026before the open | $24.70M | -19.3% | -$0.06 | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 10, 2025before the open | $7.50M | +7400.0% | -$0.28 | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 12, 2025after the close | $3.60M | +620.0% | -$0.63 | Release |
| Q1 FY2025ended Mar 31, 2025 | May 12, 2025after the close | $4.70M | +327.3% | -$0.92 | Release |
| Q4 FY2024ended Dec 31, 2024 | Mar 5, 2025after the close | $30.60M | -49.0% | $0.55 | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 4, 2024before the open | $100.00K | -98.1% | -$0.75 | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 7, 2024before the open | $500.00K | -82.8% | -$0.82 | Release |
| Q1 FY2024ended Mar 31, 2024 | May 8, 2024before the open | $1.10M | -88.9% | -$0.76 | Release |
| Q4 FY2023ended Dec 31, 2023 | Feb 28, 2024before the open | $60.00M | +823.1% | -$0.23 | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 3, 2023before the open | $5.30M | +12519.0% | -$0.55 | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 2, 2023before the open | $2.90M | -54.7% | -$0.56 | Release |
| Q1 FY2023ended Mar 31, 2023 | May 5, 2023before the open | $9.90M | +45.6% | -$0.71 | Release |
| Q4 FY2022ended Dec 31, 2022 | Feb 22, 2023before the open | $6.50M | -48.0% | -$0.88 | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 2, 2022before the open | $42.00K | -99.3% | -$0.81 | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 3, 2022before the open | $6.40M | – | -$0.78 | Release |
| Q1 FY2022ended Mar 31, 2022 | May 4, 2022before the open | $6.80M | – | -$0.74 | Release |
| Q4 FY2021ended Dec 31, 2021 | Feb 24, 2022before the open | $12.50M | – | -$0.61 | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 8, 2021before the open | $6.20M | – | -$0.57 | Release |
| Q2 FY2021ended Jun 30, 2021 | Aug 4, 2021before the open | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | May 5, 2021before the open | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Jan 19, 2021after the close | – | – | – | Filing |
| Q3 FY2020ended Sep 30, 2020 | Nov 5, 2020after the close | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Guidance
Editas Medicine has not given guidance in its releases
Many companies give their outlook only on the conference call or not at all. When Editas Medicine puts a forecast in an earnings release, it is listed here with the exact sentence.
Press releases
Releases Editas Medicine filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Results
- News
- Update
- Update
- Results
- Update
- Results
- Results
- Update
- Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development CandidateUpdate
- Results
- Update
- Update
See a number that looks wrong?